ClinicalTrials.gg
CompletedNCT01175226RHINOUpdated May 31, 2018Results posted

A Phase 2 Study of BTA798 in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

A Phase 2 interventional study of BTA798 and Placebo in Rhinovirus, sponsored by Biota Scientific Management Pty Ltd. Completed at 43 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-05-31.

Sponsored by Biota Scientific Management Pty Ltd · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study aims to evaluate the safety, tolerability and effectiveness of BTA798 on

  • shortening the length and reducing the symptoms of human rhinovirus infection (also known as the common cold),
  • controlling asthma symptoms, and
  • lowering the risk of asthma symptoms worsening in subjects with asthma.
Read the detailed description

Subjects with a previous diagnosis of asthma will be pre screened within 90 days prior to enrolment. If a subject develops symptoms of human rhinovirus (HRV) infection they will visit the site for assessment. Symptomatic subjects meeting all eligibility criteria will be invited to enroll.

02

Conditions studied

  • Rhinovirus

Keywords

  • Human rhinovirus
  • Aviragen Therapeutics, Inc.
  • Aviragen Therapeutics
  • Aviragen
03

In context

Lead sponsor

Biota Scientific Management Pty Ltd is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects aged 18-70 years
  • Diagnosis of asthma consistent with Global Initiative for Asthma (GINA) steps 1 to 3
  • Presumptive human rhinovirus infection

Exclusion criteria

Exclusion Criteria:

  • Current severe asthma exacerbation
  • Severe asthma, GINA steps 4 or higher
  • Uncontrolled or medical condition, disease or event which could impact subject safety and/or study evaluations and/or compliance to the protocol
  • Current smoker, ex-smoker of \<1 year, or history of smoking >/=10 pack years.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    BTA798

    Drug: BTA798

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugBTA798

    BTA798 twice daily

  • DrugPlacebo

    Placebo twice daily

    Also known as: Glucose

06

What researchers measure

Primary outcomes

  1. Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire

    Daily Change in WURSS-21 Severity Score Averaged over Days 2 to 4. The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire is an evaluative illness-specific outcomes instrument designed to assess the severity of cold symptoms and the impact of the common cold (range 0-140), with higher scores indicating more symptoms and functional impairment.

    Time frame: Days 2-4

07

Results

Posted Jun 1, 2017

Participant flow

Participant flow — Overall Study
MilestoneBTA798Placebo
Started155145
Completed144140
Not completed115

Outcome measures

PrimaryWisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire

Daily Change in WURSS-21 Severity Score Averaged over Days 2 to 4. The Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire is an evaluative illness-specific outcomes instrument designed to assess the severity of cold symptoms and the impact of the common cold (range 0-140), with higher scores indicating more symptoms and functional impairment.

Time frame:
Days 2-4
Reported as:
Least squares mean · Scores on a scale
Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire
Scores on a scaleBTA798Placebo
Wisconsin Upper Respiratory Symptom Survey-21 (WURSS-21) Questionnaire-9.12 ± 1.403-5.11 ± 1.184
Statistical analysis
  • BTA798 vs Placebo · ANCOVA · p = 0.020

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BTA7980/154 (0%)0/154 (0%)22/154 (14.3%)
Placebo0/145 (0%)0/145 (0%)18/145 (12.4%)
Most frequent other events
Most frequent other events
EventBTA798Placebo
HeadacheNervous system disorders7/1546/145
Upper Respiratory Tract InfectionInfections and infestations5/1545/145
SinusitisInfections and infestations5/1544/145
AsthmaRespiratory, thoracic and mediastinal disorders5/1543/145

Baseline characteristics

Safety population - all randomized subjects who received at least 1 dose of investiational product.

Age, Continuous
Age, Continuous(years)BTA798PlaceboTotal
Mean40.6 ± 14.3442.0 ± 13.6941.3 ± 14.02
Sex: Female, Male
Sex: Female, Male(Participants)BTA798PlaceboTotal
Female11495209
Male405090
Region of Enrollment
Region of Enrollment(participants)BTA798PlaceboTotal
United States154145299
08

Study locations

43 sites
  • Research Site
    Scottsdale, Arizona 85251, United States
  • Research Site
    Little Rock, Arkansas 72205, United States
  • Research Site
    Fountain Valley, California 92708, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Waterbury, Connecticut 06709, United States
  • Research Site
    Hialeah, Florida 33016, United States
  • Research Site
    Bangor, Maine 04401, United States
  • Research Site
    Baltimore, Maryland 21236, United States
  • Research Site
    Bethesda, Maryland 20814, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Saint Louis, Missouri 63141, United States
  • Research Site
    Omaha, Nebraska 68130, United States
  • Research Site
    Omaha, Nebraska 68134, United States
  • Research Site
    Papillion, Nebraska 68046, United States
  • Research Site
    Albuquerque, New Mexico 87108, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Newburgh, New York 12550, United States
  • Research Site
    North Syracuse, New York 13212, United States
  • Research Site
    Rockville Centre, New York 11570, United States
  • Research Site
    Asheville, North Carolina 28801, United States
  • Research Site
    Raleigh, North Carolina 27612, United States
  • Research Site
    Fargo, North Dakota 58103, United States
  • Research Site
    Cincinnati, Ohio 45242, United States
  • Research Site
    Cincinnati, Ohio 45267, United States
  • Research Site
    Oklahoma City, Oklahoma 73120, United States
  • Research Site
    Oklahoma City, Oklahoma 73131, United States
  • Research Site
    Lake Oswego, Oregon 97035, United States
  • Research Site
    Medford, Oregon 97504, United States
  • Research Site
    Hershey, Pennsylvania 17033, United States
  • Research Site
    Philadelphia, Pennsylvania 19115, United States
  • Research Site
    Pittsburgh, Pennsylvania 15221, United States
  • Research Site
    Pittsburgh, Pennsylvania 15241, United States
  • Research Site
    Upland, Pennsylvania 19013, United States
  • Research Site
    East Providence, Rhode Island 02914, United States
  • Research Site
    Lincoln, Rhode Island 02865, United States
  • Research Site
    Providence, Rhode Island 02906, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Waco, Texas 76712, United States
  • Research Site
    South Burlington, Vermont 05403, United States
  • Research Site
    Richmond, Virginia 23229, United States
  • Research Site
    Greenfield, Wisconsin 53228, United States
  • Research Site
    Madison, Wisconsin 53792, United States
  • Research Site
    West Allis, Wisconsin 53227, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Mar 2012 and a completion of Mar 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2017, 5 years 3 months after primary completion. A results delay was requested in Sep 2013.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2010
First posted
Aug 4, 2010
Start
Aug 2010
Primary completionActual
Mar 2012
CompletionActual
Mar 2012
Results delay requested
Sep 12, 2013
Results first posted
Jun 1, 2017
Last update
May 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01175226
Lead sponsor
Biota Scientific Management Pty Ltd
Responsible party
Sponsor
First posted
Aug 4, 2010
Start date
Aug 2010
Primary completion
Mar 2012
Completion
Mar 2012
Results posted
Jun 1, 2017
Last update
May 31, 2018

Study contacts

John Lambert, PhD
study director · Biota Scientific Management Pty Ltd

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vapendavir

Start the discussion